Alcon

Aurion Biotechnologies is a clinical-stage biotech company focused on developing advanced therapies for ocular diseases, particularly those leading to blindness. Based in Seattle, Boston, and Tokyo, the company aims to transform the lives of millions by restoring vision through innovative cell therapies. Its lead candidate targets corneal edema and is one of the first clinically validated cell therapies in corneal care. The process involves culturing healthy cells from a donor cornea using a proprietary method, allowing cells from a single donor to potentially treat over 100 recipient eyes. Clinical trials in Japan have shown that patients experience significant and lasting improvements in corneal health indicators, including visual acuity and corneal thickness.

LENSAR, Inc. is a commercial-stage medical device company based in Orlando, Florida, established in 2004. It specializes in the design, development, and marketing of advanced femtosecond laser systems aimed at improving cataract surgery outcomes. The company's flagship product, the LENSAR Laser with Streamline IV, enhances the precision and efficiency of refractive cataract surgery by incorporating advanced features such as superior imaging capabilities and customizable treatment planning. This system assists surgeons in managing astigmatism and optimizing refractive results through innovative technology like the proprietary Augmented Reality™ 3-D model and the IntelliAxis Refractive Capsulorhexis® feature. These advancements facilitate accurate toric intraocular lens alignment and streamline surgical workflows, ultimately improving patient outcomes. LENSAR continues to expand its platform's capabilities, enabling the treatment of additional corneal conditions and enhancing the overall surgical experience for both patients and surgeons.

Ocumension Therapeutics is a China-based ophthalmic pharmaceutical platform company focused on the identification, development, and commercialization of innovative ophthalmic therapies. The company aims to address significant unmet medical needs in the ophthalmology sector within China by offering a comprehensive pharmaceutical solution. Ocumension Therapeutics has established a robust platform that integrates specialized capabilities across the entire development cycle of ophthalmic drugs, including research and development, manufacturing, and commercialization. Its diverse portfolio of product candidates features several treatments such as OT-401 (YUTIQ), OT-101, OT-301 (NCX 470), and OT-1001 (ZERVIATE), among others. By leveraging its first-mover advantage and specialized expertise, Ocumension Therapeutics aspires to become a leader in the Chinese ophthalmology market.

BELKIN Vision focuses on developing a laser device that aids healthcare professionals in the treatment of glaucoma. The company's technology offers a non-invasive, non-contact, instantaneous, painless, and automated approach to laser therapy. By promoting accessibility to first-line drop-less glaucoma care, BELKIN Vision enables any ophthalmologist to effectively treat patients. This innovation aims to enhance treatment outcomes and improve the overall quality of care for individuals suffering from glaucoma.

Aerie Pharmaceuticals is a biotechnology company dedicated to the discovery, development, and commercialization of innovative therapies for various eye diseases. Founded in 2005, the company has its headquarters in Bridgewater, New Jersey, and research facilities in Research Triangle Park, North Carolina. Aerie's portfolio includes Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension; Rocklatan, a fixed-dose combination of Rhopressa and latanoprost for similar indications; AVX-012, a clinical-stage product candidate for dry eye; and AR-1105 and AR-13503 sustained-release implants for retinal diseases. The company collaborates with DSM on research, development, and licensing agreements.

EYSUVIS Portfolio of dry eye disease therapies and medications designed to make ocular surgery easier.

Aurion Biotechnologies is a clinical-stage biotech company focused on developing advanced therapies for ocular diseases, particularly those leading to blindness. Based in Seattle, Boston, and Tokyo, the company aims to transform the lives of millions by restoring vision through innovative cell therapies. Its lead candidate targets corneal edema and is one of the first clinically validated cell therapies in corneal care. The process involves culturing healthy cells from a donor cornea using a proprietary method, allowing cells from a single donor to potentially treat over 100 recipient eyes. Clinical trials in Japan have shown that patients experience significant and lasting improvements in corneal health indicators, including visual acuity and corneal thickness.

Ivantis Inc. is a medical device company based in Irvine, California, focused on developing innovative treatments for primary open-angle glaucoma. Founded in 2007, the company specializes in a minimally invasive intracanalicular scaffold that alleviates high intraocular pressure by restoring the natural outflow pathway in Schlemm's canal. This device aims to provide a less invasive and more effective solution for the over 60 million individuals worldwide affected by this condition. In addition to its primary focus on glaucoma, Ivantis intends to explore innovative treatments for other ophthalmic diseases as it expands its product offerings. The company also provides a Session Persistence Server to support clinical trials, ensuring data protection for telnet task workers and terminal emulation users across various devices and operating systems.

PowerVision, Inc. is a company that specializes in the development of innovative intraocular lenses aimed at restoring vision for individuals suffering from presbyopia and cataracts. Founded in 2002 and based in Belmont, California, PowerVision has created the FluidVision accommodating intraocular lens, which utilizes a unique fluid-controlled mechanism to mimic the natural function of a healthy eye. This technology allows users to dynamically adjust their focus for clear vision at all distances, potentially liberating millions from the need for glasses or other vision correction methods. The FluidVision lens is designed to meet the clinical and lifestyle needs of patients, offering a significant advancement in vision correction surgery. PowerVision's approach addresses the visual impairments faced by over 20 million people in the United States with cataracts and more than 90 million individuals affected by presbyopia, particularly those in their 40s and 50s.

TrueVision Systems specializes in high-definition digital imaging and 3D visualization technology aimed at enhancing stereomicroscopy in surgical and educational environments. The company has developed a patented vision system and smart medical software packages applicable across various surgical disciplines. Founded by Dr. Michael Weissman, a leading expert in digital stereoscopic imaging, TrueVision addresses the need for improved visualization in existing surgical microscopes. The firm's flagship product, the TrueVision 3DHD vision system, is designed for microsurgery and incorporates advanced features such as robotics, integrated patient data, and intraoperative connectivity to boost surgical accuracy and efficiency. In addition to manufacturing its own products, TrueVision licenses its technology to both medical and non-medical manufacturers for diverse stereoscopic visualization applications. With a team comprised of industry veterans and PhD-level technical staff, the company is committed to developing innovative solutions that enhance surgical outcomes and improve the education of microsurgery.

Tear Film Innovations Inc. is a medical device company based in San Diego, California, specializing in the treatment of evaporative dry eye and related conditions such as meibomian gland dysfunction (MGD) and blepharitis. Founded in 2014, the company has developed the iLux Dry Eye Treatment System, a handheld device that allows eye care professionals to quickly evaluate and treat dry eye patients in under ten minutes. The iLux system uses targeted heating and compression to unblock meibomian glands, addressing the most common form of dry eye that affects over 330 million people worldwide. Additionally, the company offers BlephaRx, which targets both the symptoms and underlying causes of evaporative dry eye. As of December 2018, Tear Film Innovations operates as a subsidiary of Alcon, Inc.

Transcend Medical, Inc. is an ophthalmic device company dedicated to developing medical devices for the treatment of glaucoma, a leading cause of irreversible blindness in adults. Founded in 2005 and based in Menlo Park, California, the company emerged from ForSight Labs and focuses on minimally invasive solutions to replace traditional invasive therapies. Its flagship product, the CyPass Micro-Stent, is designed to be inserted during routine cataract surgery to help reduce intraocular pressure. Transcend Medical also offers the Vold Gonio Lens for use in micro-invasive glaucoma surgery and provides clinical trial services. The CyPass Micro-Stent received CE mark approval in 2008 and has been evaluated in various clinical studies, including the COMPASS multi-center trial. The company operates as a subsidiary of Alcon Holdings, Inc.

WaveTec Vision, founded in 1997 and located in Aliso Viejo, California, specializes in advanced wavefront measurement technology for cataract surgery. The company's proprietary intraoperative aberrometer system, ORange, allows surgeons to measure the eye and enhance surgical outcomes in real-time. By facilitating the convergence of refractive and cataract surgery, WaveTec Vision aims to improve the overall efficacy and precision of these procedures, ultimately benefiting patient care and satisfaction.

SensoMotoric Instruments GmbH is a leading developer and marketer of application-specific gaze and eye tracking systems, original equipment manufacturer solutions, and medical applications. Established in 1991 and headquartered in Teltow, Germany, with additional offices in Berlin and Boston, the company offers a range of products tailored for various sectors, including market research, neuromarketing, neuroscience, ophthalmology, and education. Their offerings include eye tracking platforms for desktop and mobile devices, wearable eye tracking glasses, and solutions for virtual and augmented reality applications. SensoMotoric Instruments serves a global customer base and is recognized for its innovative products and services, with over 6,000 eye tracker systems operational worldwide.

LensX Lasers is a developer of surgical lasers used for the reparation of cataracts.

ESBATech, founded in 1998 as a spin-off from the University of Zurich, specializes in the development of fully human antibody fragments for therapeutic purposes. The company utilizes its proprietary single-chain antibody frameworks to create product candidates targeting clinically relevant diseases. ESBATech aims to deliver high concentrations of these therapeutic antibody fragments to specific sites while minimizing systemic exposure, thereby reducing the risk of adverse drug reactions. In addition to its innovative antibody development, the company offers drug development services and manages various development programs, positioning itself as a leader in the field of targeted therapies.

Wavelight specializes in the design, manufacture, and marketing of advanced laser systems for various medical, aesthetic, and industrial applications. Its medical focus encompasses ophthalmology, dermatology, and urology, with a particular emphasis on correcting vision defects. The company's innovative technologies include electronic guidance systems for the precise positioning of intraocular lenses and eye-tracking systems specifically for laser procedures. These advancements enhance the accuracy and reproducibility of refractive cataract surgeries, ultimately improving patient outcomes.